Form 4: Corcept Therapeutics Executive William Guyer Exercises Options and Sells Shares
SEC Form 4 Filing
William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock on August 1, 2024, according to a recent SEC filing.
Summary
- On August 1, 2024, William Guyer, the Chief Development Officer of Corcept Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $21.65 per share.
- Simultaneously, Guyer sold 10,000 shares of Corcept Therapeutics common stock at a price of $38.67 per share.
- Following these transactions, Guyer directly owns 6,039 shares of Corcept Therapeutics common stock.
- Guyer also holds options to purchase 480,000 shares of Corcept Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard SEC filing detailing insider transactions. No explicit positive or negative implications can be derived.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transaction could have a minor impact on shareholders due to the change in ownership, but it's unlikely to be significant given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 08/16/2021 | Vesting Commencement Date for stock options |
| 09/01/2023 | Date of restricted stock awards grant |
| 12/01/2023 | Date of restricted stock units grant |
| 08/01/2024 | Date of transaction: exercise of stock options and sale of shares |
| 08/05/2024 | Date of Form 4 filing |
| 09/01/2031 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.